相关实验视频

Updated: May 16, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

日本乳腺癌男性和女性的比较净生存分析:一个基于人口的研究

Daisy Sibale Mojoo^1,2, Isao Oze³, Hiroshi Tsuge³

¹Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.

|March 31, 2025

概括

男性乳腺癌 (MBC) 的存活率与日本女性乳腺癌 (FBC) 的存活率相当. 这项大型研究发现,1993年至2011年间诊断的男性和女性的净生存率没有显著的基于性别的差异.

科学领域:

在瘤学瘤学.
流行病学流行病学
公共卫生公共卫生

背景情况:

与女性乳腺癌 (FBC) 相比,男性乳腺癌 (MBC) 是罕见的,研究不足.
只有有限的大型研究比较了日本的MBC和FBC预后.
了解MBC预后对于改善患者的治疗结果至关重要.

研究的目的:

为了比较男性乳腺癌 (MBC) 患者与日本女性乳腺癌 (FBC) 患者的预后.
估计和分层MBC和FBC的5年和10年净生存率 (NS).
为了确定乳腺癌存活率的任何基于性别的差异.

主要方法:

在日本 (1993-2011) 诊断的181540例乳腺癌病例 (1058名男性,180,482名女性) 的分析.
估计5年和10年净生存 (NS),按性别,时期,年龄,阶段和组织学分层.
根据关键预后因素调整的过度危险比率 (EHR) 的计算;Cochran的Q测试异质性.

主要成果:

整体5年NS:MBC90.7%,FBC88.3%. 在5年NS中,MBC的比例为90.7%,FBC的比例为88.3%. 总体而言,10年的NS:MBC 83.7%,FBC 79.1%. 这是一个很好的结果.
MBC的存活率与FBC的存活率相似,在5年 (0.88) 和10年 (0.86) 的存活率中,没有显著的超额危险比率 (EHR).
异质性分析显示,在各层次的生存中,没有基于性别的显著差异.

结论:

在日本,男性乳腺癌 (MBC) 的预后与女性乳腺癌 (FBC) 的预后相当.
男性和女性乳腺癌患者的生存率在调整预后因素时没有显著差异.
这项研究提高了在日本乳腺癌存活率的更广泛背景下对MBC预后的理解.

关键词:

女性乳腺癌的女性乳腺癌.这是一项以人口为基础的研究.预后预后预后幸存率幸存率生存率

更多相关视频

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...